EFFICACY AND SAFETY OF TILDRAKIZUMAB IN PATIENTS WITH AND WITHOUT METABOLIC SYNDROME: 5-YEAR POOLED DATA FROM reSURFACE 1 AND RESURFACE 2

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Mehta, N. [2 ]
Menter, A. [3 ,4 ]
Mendelsohn, A. M. [5 ]
Rozzo, S. [5 ]
Lebwohl, M. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY 10029 USA
[2] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA
[3] Baylor Scott & White, Div Dermatol, Dallas, TX USA
[4] Texas A&M Coll Med, Div Dermatol, Dallas, TX USA
[5] Sun Pharmaceut Ind Inc, Med Affairs, Princeton, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年 / 80卷
关键词：
D O I：
10.1136/annrheumdis-2021-eular.1827
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0544
引用
收藏
页码：1304 / 1305
页数：2
相关论文
共 50 条
  • [1] Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2
    Fernandez, A. P.
    Dauden, E.
    Gerdes, S.
    Lebwohl, M. G.
    Menter, M. A.
    Leonardi, C. L.
    Gooderham, M.
    Gebauer, K.
    Tada, Y.
    Lacour, J. P.
    Bianchi, L.
    Egeberg, A.
    Pau-Charles, I.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Mehta, N. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (10) : 1774 - 1783
  • [2] Relationship of serum glucose to efficacy and safety of tildrakizumab treatment for psoriasis in patients with and without metabolic syndrome from reSURFACE 1 and reSURFACE 2
    Lebwohl, Mark G.
    Menter, Alan
    Rozzo, Stephen J.
    Parno, Jeff
    Mendelsohn, Alan M.
    Mehta, Nehal N.
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB163 - AB163
  • [3] Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) : 398 - 407
  • [4] Effect of metabolic syndrome on efficacy and safety in patients with psoriasis treated with etanercept or tildrakizumab: Post hoc analysis of 2 phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Gottlieb, Alice B.
    Mehta, Nehal N.
    Lebwohl, Mark
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB50 - AB50
  • [5] Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks
    Haar, Elke L. M. T. E. R.
    Van Den Reek, Juul M. P. A.
    Du Jardin, Kristian Gaarn
    Barbero-castillo, Almudena
    De Jong, Elke M. G. J.
    Lubeek, Satish F. K.
    ACTA DERMATO-VENEREOLOGICA, 2023, 103
  • [6] Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Leonardi, Craig L.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 519 - 522
  • [7] Tildrakizumab efficacy by metabolic syndrome status in psoriasis: 3-year data from the phase 3 reSURFACE 1 study
    Lebwohl, M. G.
    Mehta, N. N.
    Gottlieb, A. B.
    Rozzo, S.
    Parno, J.
    Rozzo, S. J.
    Menter, A. M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 91 - 91
  • [8] Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
  • [9] Stability of PASI <3 response to tildrakizumab through 5 years: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials
    Thaci, Diamant
    Piaserico, Stefano
    Gaarn Du Jardin, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB113 - AB113
  • [10] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
    Elewski, Boni
    Han, George
    Rozzo, Stephen J.
    Gogineni, Ranga
    Schenkel, Brad
    Guenthner, Scott
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
12345